Ceptur Therapeutics is a pre-clinical stage biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/19/22 | $75,000,000 | Series A |
Affinity Asset Advisors Boxer Capital Bristol-Myers Squibb Janus Henderson Investors LifeSci Venture Partners Perceptive Advisors Qiming Venture Partners  VenBio | undisclosed |
